


Dasatinib N-oxide-d8

Cat. No.:	HY-133794S
CAS No.:	1189988-36-0
Molecular Formula:	C ₂₂ H ₁₈ D ₈ ClN ₇ O ₃ S
Molecular Weight:	512.05
Target:	Drug Metabolite
Pathway:	Metabolic Enzyme/Protease
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	Dasatinib N-oxide-d8 is the deuterium labeled Dasatinib N-oxide. Dasatinib N-oxide is a minor metabolite of Dasatinib. Dasatinib is a potent and orally active dual Src/Bcr-Abl inhibitor ^{[1][2]} .
In Vitro	Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

- [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. *Ann Pharmacother*. 2019;53(2):211-216.
- [2]. Christopher LJ, et, al. Metabolism and disposition of dasatinib after oral administration to humans. *Drug Metab Dispos*. 2008 Jul;36(7):1357-64.
- [3]. Furlong MT, et, al. A validated LC-MS/MS assay for the simultaneous determination of the anti-leukemic agent dasatinib and two pharmacologically active metabolites in human plasma: application to a clinical pharmacokinetic study. *J Pharm Biomed Anal*. 2012 Jan 25;58:130-5.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA